Anebulo Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Anebulo Pharmaceuticals generated cash of -$8,090,849, which is more than the previous year. Cash used in financing activities reached the amount of -$62,354 last year. Net change in cash is therefore -$8,153,203.
Cash Flow
| 2020 | -150.77K | 0 | 3.17M |
|---|---|---|---|
| 2021 | -4.87M | 0 | 21.83M |
| 2022 | -5.43M | 0 | 0 |
| 2023 | -9.68M | 0 | 6.38M |
| 2024 | -8.09M | 0 | -62.35K |
ANEB Cash Flow Statement (2020 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
Cash at beginning of period | 11.24M | 14.54M | 19.98M | 3.02M | 0 |
Operating activities | |||||
Net income | -8.20M | -11.73M | -6.82M | -30.25M | -174.63K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 758.88K | 884.72K | 480.66K | 199.94K | 0 |
| Deferred income tax benefit | 758.88K | 884.72K | 480.66K | 199.94K | 0 |
| Changes in operating assets and liabilities: | |||||
Accounts receivable, net | 0 | 0 | 0 | 3.5K | 0 |
Inventories | 0 | 0 | 0 | -3.5K | 0 |
Accounts payable | -378.11K | 153.71K | 270.78K | 110.04K | 0 |
Cash generated by operating activities | -8.09M | -9.68M | -5.43M | -4.87M | -150.77K |
Investing activities | |||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 |
Financing activities | |||||
Common Stock Issued | 654K | 6.64M | 0 | 22.85M | 2.97M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 8.20M | 0 |
Repayments of term debt | 0 | 0 | 0 | -201.28K | -200K |
Cash used in financing activities | -62.35K | 6.38M | 0 | 21.83M | 3.17M |
Net Change In Cash | -8.15M | -3.30M | -5.43M | 16.96M | 3.02M |
Cash at end of period | 3.09M | 11.24M | 14.54M | 19.98M | 3.02M |
| Data source | Data source | Data source |